FMR LLC - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.

Quarter-by-quarter ownership
FMR LLC ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$81,774,916
+140.1%
10,689,532
+134.4%
0.01%
+133.3%
Q2 2023$34,060,188
-46.3%
4,559,597
-52.1%
0.00%0.0%
Q1 2023$63,437,846
+84.2%
9,510,922
+113.0%
0.00%0.0%
Q4 2022$34,430,661
-23.9%
4,465,715
+5.0%
0.00%
-40.0%
Q3 2022$45,233,000
+95.9%
4,251,164
+49.9%
0.01%
+150.0%
Q2 2022$23,084,000
+50.3%
2,835,852
+32.2%
0.00%
+100.0%
Q1 2022$15,363,000
-41.4%
2,145,639
+40.2%
0.00%
-50.0%
Q4 2021$26,213,000
-41.9%
1,530,226
-21.9%
0.00%
-50.0%
Q3 2021$45,099,000
-44.1%
1,959,963
-11.4%
0.00%
-33.3%
Q2 2021$80,724,0002,211,6010.01%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Obvious Management Services, L.L.C. 3,985,087$42,401,000100.00%
Two Sigma Ventures, LP 903,400$9,612,000100.00%
DCVC Opportunity Fund II GP, LLC 3,951,141$42,040,00054.37%
Data Collective IV GP, LLC 5,941,120$63,214,00049.97%
MIC Capital Management UK LLP 8,451,758$89,927,00016.21%
MV Management XI, L.L.C. 1,971,908$20,981,00015.20%
ArchPoint Investors 1,116,126$11,876,0004.85%
HARVARD MANAGEMENT CO INC 1,509,254$16,058,0002.00%
PLATINUM INVESTMENT MANAGEMENT LTD 2,251,971$23,961,0001.00%
Duquesne Family Office 1,385,950$14,747,0000.84%
View complete list of RECURSION PHARMACEUTICALS IN shareholders